Having demonstrated that the protective haplotype is most highly expressed, and the risk haplotype is expressed at lowest levels in IFNβ-treated myeloid subsets; we determined the immune genes and pathways regulated by IL7Rα signaling and thus potentially affecting MS risk in these subsets. The gene discussed is IFNB1; the disease is myeloid sarcoma.